Products Ramucirumab is commercially available as a concentrate for the preparation of an infusion solution (Cyramza). It was approved in many countries in 2015. Structure and properties Ramucirumab is a human IgG1 monoclonal antibody with a molecular mass of 147 kDa that binds to the extracellular domain of VEGFR-2. Ramucirumab is produced by biotechnological methods. … Ramucirumab
Products Bimagrumab is in clinical development at Novartis and is not currently commercially available. The antibody was developed at MorphoSys in Munich. Structure and properties Bimagrumab is a human monoclonal antibody. Effects Bimagrumab promotes skeletal muscle development. The antibody binds with high affinity to type II activin receptors and prevents the binding of the natural … Bimagrumab
Products Atezolizumab was approved as an infusion product in the United States in 2016 and in the EU and many countries in 2017 (Tecentriq). Structure and properties Atezolizumab is a humanized IgG1κ monoclonal antibody with a molecular mass of 145 kDa. Effects Atezolizumab (ATC L01XC32) has immunostimulatory and antitumor properties. The effects are due to … Atezolizumab
Products Galcanezumab was approved in the United States and EU in 2018 and in many countries in 2019 as a solution for injection in a prefilled pen and a prefilled syringe (Emgality, Eli Lilly). Structure and properties Galcanezumab is a humanized IgG4 monoclonal antibody with a molecular mass of 147 kDa against CGRP. It is … Galcanezumab
Products Secukinumab was approved as an injectable in many countries in 2015 (Cosentyx / -SensoReady). Structure and properties Secukinumab is a human IgG1κ monoclonal antibody. It is produced by biotechnological methods. The molecular mass is approximately 151 kDa. Effects Secukinumab (ATC L04AC10) binds to the cytokine interleukin-17A (IL-17A) and inhibits interaction with its receptor. As … Secukinumab
Products Denosumab is commercially available as a solution for injection in a prefilled syringe (Prolia). The antibody was approved in many countries, in the United States, and in the EU in 2010. Denosumab is also used in tumor therapy (Xgeva). This article relates to osteoporosis treatment. Structure and properties Denosumab is a human IgG2 monoclonal … Denosumab
Products Fremanezumab was approved in the United States in 2018 and in the EU and Switzerland in 2019 as a solution for injection for subcutaneous use (Ajovy). Structure and properties Fremanezumab is a humanized IgG2Δa/kappa monoclonal antibody directed against CGRP (calcitonin gene-related peptide). The antibody is produced by biotechnological methods, consists of 1324 amino acids, … Fremanezumab
Products Lanadelumab was approved as an injectable in the US and EU in 2018 and in many countries in 2019 (Takhzyro). Structure and properties Lanadelumab is a recombinant human IgG1κ monoclonal antibody with a molecular mass of 146 kDa. It is produced by biotechnological methods. Effects The effects of lanadelumab (ATC B06AC05) are based on … Lanadelumab
Products Siltuximab was approved in many countries in 2014 as a powder for a concentrate for [infusion solution>infusion] (Sylvant). Structure and properties Siltuximab is a human murine chimeric monoclonal antibody that binds human interleukin-6 (IL-6). Effects Siltuximab (ATC L04AC11) has anti-inflammatory and immunosuppressive properties. It prevents binding of human interleukin-6 to IL-6 receptors. Indications For … Siltuximab
Products Sarilumab was approved in the United States and EU in 2017 and in many countries in 2018 as a solution for injection (Kevzara, prefilled syringe, prefilled pen). Structure and properties Sarilumab is a human IgG1 monoclonal antibody with a molecular mass of 150 kDa. It is produced by biotechnological methods. Effects Sarilumab (ATC L04AC14) … Sarilumab
Products Aducanumab has been studied in phase III trials and is in the pre-approval phase. The drug is not yet commercially available. The trials were discontinued in March 2019. However, following a re-analysis, the company announced in October 2019 that it expected to file for approval. Apparently, a sufficiently high dose is required for an … Aducanumab
Products Avelumab was approved in the United States, the EU, and many countries in 2017 as a concentrate for the preparation of an infusion solution (Bavencio). Structure and properties Avelumab is a human IgG1λ monoclonal antibody against programmed cell death ligand 1 (PD-L1) with a molecular weight of 147 kDa. It is produced by biotechnological … Avelumab